Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121

Status	RECRUITING
Phase	Phase 4
Sponsor	Travere Therapeutics, Inc.
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (8)

- Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
- Male and female aged e18 years
- Participants with a kidney transplant with biopsy-proven IgAN or FSGS histological pattern in the graft.
- A period of e12 months since kidney transplantation.
- UPCR e0.5 g/g and eGFR (CKD-EPI creatinine-based formula e30 mL/min/1.73 m2.

... and 3 more (see full listing online)

Exclusion (17)

- Participant has multiorgan transplants (with the exception of pancreas and corneal transplants).
- Immunosuppressive therapy (IST) regimen for kidney transplant or other systemic chronic ISTs including enteric budesonide that is not stable for \>6 weeks prior to Day 1. Exceptions include routine changes in the dose of CNIs to meet target level.
- \<3 months after antirejection treatment and active rejection.
- Active bacterial, fungal or viral infection and/or active treatment of infection including BK virus (BKV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B and C \<3 months prior to and during the screening period.
- Current treatment for surgical complications.

... and 12 more (see full listing online)

Locations (9 total)

University of Alabama at Birmingham, Birmingham, Alabama, United States
Cornell Medical Center, New York, New York, United States
University of North Carolina Chapel Hill, Morrisville, North Carolina, United States
... and 6 more locations